Skip to main content
SpringerLink
Log in

Tumor Antigens in Pancreatic Cancer

  • Chapter
Pancreatic Cancer

Abstract

A wide array of tumor markers, including enzymes, oncofetal antigens, tumor-associated antigens, and other markers, has been used in the diagnosis and management of pancreatic cancer. The advent of hybridoma technology, with the development of monoclonal probes for tumor markers, has represented an important step in this regard, with significant contributions to both the diagnosis and management of patients with pancreatic carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pasquali C, Sperti C, D’Andrea AA, et al. Clinical value of serum tag 72 as a tumour marker for pancreatic carcinoma. Comparison with CA 19-9. Int J Pancreatol 1994; 15: 171–177.

    CAS  Google Scholar 

  2. Sperti C, Pasquali C, Guolo P, Polverosi R, Liessi G, and Pedrazzoli S. Serum tumour markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors. Cancer 1996; 78:237–243.

    Article  PubMed  CAS  Google Scholar 

  3. Steinberg W: Clinical utility of the CA 19-9 tumor associated antigen. Am J Gastroenterol 1990; 85:350–355.

    PubMed  CAS  Google Scholar 

  4. Taccone W, Mazzon W, and Belli M. Evaluation of TATI and other markers in solid tumors. Scand J Clin Lab Invest 1991; 51:25–32.

    Article  Google Scholar 

  5. Aroasio E and Piantino P. Tumor-associated inhibitor in pancreatic diseases. Scand J Clin Lab Invest 1991; 51:71–73.

    Article  Google Scholar 

  6. Saito S, Taguchi K, Nishimura N, et al. Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma. Cancer 1993; 72:381–388.

    Article  PubMed  CAS  Google Scholar 

  7. Satake K and Takeuchi T. Comparison of CA 19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 1994; 9:720–724.

    Article  PubMed  CAS  Google Scholar 

  8. Satake K, Chung YS, Umeyama K, et al. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various tumor markers. Cancer 1991; 68:149–152.

    Article  PubMed  CAS  Google Scholar 

  9. Furukawa H, Okada S, Ariyama J, et al. Clinicopathologic features of small pancreatic adenocarcinoma. Cancer 1996; 78:986–990.

    Article  PubMed  CAS  Google Scholar 

  10. Kuno N, Kurimoto K, Fukushima M, Hayakawa T, Shibata T, Suzuki T, et al. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multiinstitutions. Pancreas 1994; 9:725–730.

    Article  PubMed  CAS  Google Scholar 

  11. Azuma T, Hira M, Ito S, et al. Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Int J Cancer 1996; 67:492–497.

    Article  PubMed  CAS  Google Scholar 

  12. Parker N, Makin CA, Ching CK, et al. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM17.2/WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer 1992; 70:1062–1068.

    Article  PubMed  CAS  Google Scholar 

  13. Yiannakow JY, Newland P, Calder F, et al. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997; 349:389–392.

    Article  Google Scholar 

  14. Kropowski H, Stepleweski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 1979; 5:957–972.

    Article  Google Scholar 

  15. Magnani J, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982; 257:14365–14369.

    PubMed  CAS  Google Scholar 

  16. Itkowitz SH and Kim YS. New carbohydrate tumor markers. Gastroenterology 1986; 90: 491–494.

    Google Scholar 

  17. Tempero MA, Uchida E, Tkasaki H, et al. Relationship of carbohydrate antigen CA 19-9 and Lewis antigen in pancreatic cancer. Cancer Res 1987; 47:5501–5503.

    PubMed  CAS  Google Scholar 

  18. Takasaki H, Uchida E, Tempero M, et al. Correlative study on expression of CA 19-9 and DUPAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res 1988; 48:1435–1438.

    PubMed  CAS  Google Scholar 

  19. Von Rosen A, Linder S, Harmenberg U, and Pegert S. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 1993; 8:160–165.

    Article  Google Scholar 

  20. Yazawa S, Asao T, Izawa H, et al. The presence of CA 19-9 in serum and saliva from Lewis negative cancer patients. Japn J Cancer Res 1987; 79:538.

    Article  Google Scholar 

  21. Masson P, Pålsson B, and Andrén-Sandberg Å: Cancer associated tumor markers CA 19-9 and CA 50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br J Cancer 1990; 62:118-121.

    Google Scholar 

  22. Arends JW. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma 1983; 2:219–229.

    Article  PubMed  CAS  Google Scholar 

  23. Atkinson BF, Ernst CS, Herlyn M, et al. Gastrointestinal immunoperoxidase assay. Cancer Res 1982;42:4820–4823.

    PubMed  CAS  Google Scholar 

  24. Ritts RE, Del Villano BC, Go VLW, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using NCI serum bank. Int J Cancer 1984; 33:339–345.

    Article  PubMed  Google Scholar 

  25. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983; 29:549–552.

    PubMed  Google Scholar 

  26. Craxi A, Patti C, and Aragona E. Serum CA 19-9 levels in patients with hepatocellular carcinoma or cirrhosis. Ital J Gastroenterol 1985; 17:288–289.

    Google Scholar 

  27. Albert MB, Steinberg W, and Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988; 33:1223–1225.

    Article  PubMed  CAS  Google Scholar 

  28. Paganuzzi M, Onetto M, Marroni P, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary disease. Cancer 1988; 61:2100–2108.

    Article  PubMed  CAS  Google Scholar 

  29. Tatsuta M, Yamamura H, Iishi H, et al. Values of CA 19-9 in the serum, pure pancreatic juice and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985;2669–2673.

    Google Scholar 

  30. Schmiegel WH, Kreiker W, Eberl W, et al. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut 1985; 26:456–460.

    Article  PubMed  CAS  Google Scholar 

  31. Malesci A, Tommasini MA, Bonato C, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92:60–67.

    PubMed  CAS  Google Scholar 

  32. Chen YF, Mai CR, Tie ZJ, et al. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma. Chinese Med J 1989; 102:333–337.

    CAS  Google Scholar 

  33. Gentiloni N, Caradonna MD, Costamagna G, et al. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am J Gastroenterol 1995; 90:1069–1072.

    PubMed  CAS  Google Scholar 

  34. Podolsky DK: Serologie markers in the diagnosis and management of pancreatic carcinoma. World J Surg 1984; 8:822.

    Article  PubMed  CAS  Google Scholar 

  35. Satake K, Takeuchi T, Homma T, and Ozaki H. CA 19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994; 9:703–706.

    Article  PubMed  CAS  Google Scholar 

  36. Frebourg T, Bercoff E, Manchon N, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer: a prospective study of 866 patients. Cancer 1988; 62:2287–2290.

    Article  PubMed  CAS  Google Scholar 

  37. Chang JH and Takeuchi T. Clinical significance of measurement of Span-1 antigen in the diagnosis of pancreatic cancer. J Japn Pancreas Soc 1990; 5:80–88.

    Google Scholar 

  38. Pleskow DK, Berger H, Gyves J, et al. Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110:704–709.

    PubMed  CAS  Google Scholar 

  39. Ji-yao W, Fu-Zhen C, and Yong-Zhang Y. Evaluation of non-invasive diagnostic tests in detecting cancer of the pancreas. Chinese Med J 1990; 103:817–820.

    Google Scholar 

  40. Van den Bosch RP, van Eijck CHJ, Mulder PGH, Jeekel J: Serum CA 19-9 determination in the management of pancreatic cancer. Hepatogastroenterology 1996; 43:710–713.

    PubMed  Google Scholar 

  41. Forsmark CE, Lambiase L, and Vogel S. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9. Pancreas 1994; 9:731–734.

    Article  PubMed  CAS  Google Scholar 

  42. Safi F, Schlosser W, Falkenreck S, and Beger H. CA 19-9 serum course and prognosis of pancreatic cancer. Int J Pancreatol 1996; 20:155–161.

    Article  PubMed  CAS  Google Scholar 

  43. Lundin J, Roberts P, and Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994; 69:515–519.

    Article  PubMed  CAS  Google Scholar 

  44. Sperti C, Pasquali C, Catalini S, et al. CA 19-9 as a prognostic index after resection for pancreatic cancer. Oncology 1993; 52:137–141.

    CAS  Google Scholar 

  45. Gattani AM, Mandeli J, and Bruckener HW. Tumor markers in patients with pancreatic carcinoma. Cancer 1996; 78:57–62.

    Article  PubMed  CAS  Google Scholar 

  46. Willet C, Daly W, and Warshaw A. CA 19-9 is an index of response to neoadjuvant chemoradiation therapy in pancreatic cancer. Am J Surg 1996; 172:350–352.

    Article  Google Scholar 

  47. Glenn J, Steinberg W, Kurtzman S, et al. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6:462–468.

    PubMed  CAS  Google Scholar 

  48. Beretta E, Malesci A, Zerbi A, et al. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987; 60:2428–2431.

    Article  PubMed  CAS  Google Scholar 

  49. Tian F, Appert H, Myles J, and Howard J. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992; 215:350–355.

    Article  PubMed  CAS  Google Scholar 

  50. Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol 1983; 71:178–181.

    Article  PubMed  CAS  Google Scholar 

  51. Mansson JE, Fredman P, Nilsson O, et al. Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma. Biochim Biophys Acta 1985; 834:110–117.

    Article  PubMed  CAS  Google Scholar 

  52. Haglund C, Roberts PJ, Manko H, and Kuusela P. Tumor markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol 1992; 27:169–174.

    Article  PubMed  CAS  Google Scholar 

  53. Pasquali C, Sperti C, D’Andrea AA, et al. CA 50 compared with CA 19-9 as serum tumour marker for pancreatic carcinoma. Ital J Gastroenterol 1994; 26:169–173.

    PubMed  CAS  Google Scholar 

  54. Molina LM, Diez M, Cava MT, et al. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9 and CA 50. Int J Biol Markers 1990; 5:127–132.

    PubMed  CAS  Google Scholar 

  55. Kobayashi T, Kawa S, Tokoo M, et al. Comparative study of CA 50 (time-resolved fluoroimmunoassay), Span-1, and C A 19-9 in the diagnosis of pancreatic cancer. Scand J Gastroenterol 1991; 26:787–797.

    Article  PubMed  CAS  Google Scholar 

  56. Benini L, Cavallini G, Zordan D, Rizzotti P, Rigo L, Brocco G, et al. A clinical evaluation of monoclonal (CA 19-9, CA 50, CA 12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3:61–66.

    Article  PubMed  CAS  Google Scholar 

  57. Chung YS, Ho JJ, Kim YS, et al. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987; 60:1636–1643.

    Article  PubMed  CAS  Google Scholar 

  58. Kawa S, Tokoo M, Oguchi H, et al. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glyconconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas 1994; 9:692–697.

    Article  PubMed  CAS  Google Scholar 

  59. Kiriyama S, Hayakawa T, Kondo T, et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990; 65:1557–1561.

    Article  PubMed  CAS  Google Scholar 

  60. Kawa S, Oguchi H, Kobayashi T, et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991; 64:899–902.

    Article  PubMed  CAS  Google Scholar 

  61. Ferrara C, Basso D, Fabris C, et al. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer. Tumori 1991; 77:56–60.

    PubMed  CAS  Google Scholar 

  62. Ohshio G, Manabe T, Watanabe Y, et al. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA 19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990; 85:1370–1376.

    PubMed  CAS  Google Scholar 

  63. Cooper EH, Forbes MA, and Taylor M. An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease. Brit J Cancer 1990; 62:1004–1005.

    Article  PubMed  CAS  Google Scholar 

  64. Fabris C, Malesci A, Basso D, et al. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction. Br J Cancer 1991; 63:451–453.

    Article  PubMed  CAS  Google Scholar 

  65. Lindholm L, Johansson C, Jansson EL, et al. An immuno-radiometric assay (IRMA) for the CA 50 antigen. In: Holmgren J (ed), Tumor marker antigen, Studentlitteratur, Lund, Sweden, 1985; pp. 123–133.

    Google Scholar 

  66. Rothlin M, Joller H, and Largiadèr F. CA 242 is a new tumor maker for pancreatic cancer. Cancer 1993; 71:701–707.

    CAS  Google Scholar 

  67. Plebani M, Basso D, Navaglia F, et al. Is CA 242 really a new tumor marker for pancreatic adenocarcinoma? Oncology 1995; 52:19–23.

    Article  PubMed  CAS  Google Scholar 

  68. Kuusela P, Haglund C, and Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 1991; 63:636–640.

    Article  PubMed  CAS  Google Scholar 

  69. Pasanen PA, Eskelinen M, Partanen K, et al. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 1994; 69:562–565.

    Article  PubMed  CAS  Google Scholar 

  70. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, and Alhava E. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study. Anticancer Res 1992; 12:1689–1694.

    Google Scholar 

  71. Haglund C, Lindgren J, Roberts PJ, and Nordling S. Tissue expression of the tumor associated antigen CA 242 in benign and malignant pancreatic lesions. Br J Cancer 1989; 60:845.

    Article  PubMed  CAS  Google Scholar 

  72. Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994; 70:481-486.

    Google Scholar 

  73. Banfi G, Zerbi A, Pastori S, et al. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993; 39:420–423.

    PubMed  CAS  Google Scholar 

  74. Pålsson B, Masson P, and Andrén-Sandberg Å. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases. Scand J Gastroenterol 1993; 28:981–987.

    Article  PubMed  Google Scholar 

  75. Pasanen PA, Eskelinen M, Partanen K, et al. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients. Anticancer Res 1992; 12:2309–2314.

    PubMed  CAS  Google Scholar 

  76. Nilsson O, Johansson C, Glimelius B, et al. Sensitivity and specificity of CA 242 in gastrointestinal cancer. A comparison with CEA, CA 50 and CA 19-9. Br J Cancer 1988; 65:215–221.

    Google Scholar 

  77. Pasanen PA, Eskelinen M, Pikkarainen P, et al. Clinical evaluation of a new serum tumor marker CA 242 in pancreatic carcinoma. Br J Cancer 1989; 60:845.

    Article  Google Scholar 

  78. Furuya N, Kawa S, Hasebe O, et al. Comparative study of CA 242 and CA 19-9 in chronic pancreatic. Br J Cancer 1996; 73:372-376.

    Google Scholar 

  79. Bosslet K, Kern HF, Kanzy EJ, et al. A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. Cancer Immunol Immunother 1986; 23:185–191.

    Article  PubMed  CAS  Google Scholar 

  80. Büchler M, Friess H, Schultheiss K, et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991; 68:1507–1512.

    Article  PubMed  Google Scholar 

  81. Büchler M, Friess H, Malfertheiner P, et al. Studies of pancreatic cancer utilizing monoclonal antibodies. Int J Pancreatol 1990; 7:151–157.

    PubMed  Google Scholar 

  82. Friess H, Buchler M, Auerbach B, et al. CA 494-a new tumor marker for the diagnosis of pancreatic cancer. Int J Cancer 1993; 53:759–763.

    Article  PubMed  CAS  Google Scholar 

  83. Bjöklund N and Björklund V. Antigenecity of pooled human malignant and normal tissues by cyto-immunological technique: presence of an insoluble, heatlabile tumor antigen. Int Arch Allergy 1957; 10:153–184.

    Article  Google Scholar 

  84. Ochi Y, Ura Y, Hamazu H, et al. Immunological study of tissue polypeptide antigen (TPA)—demonstration of keratin-like sites and blood group antigen-like sites on TPA molecules. Clin Chem Acta 1985; 151:157–167.

    Article  CAS  Google Scholar 

  85. Meduri F, Doni MG, Merenda R, et al. The role of the leukocyte adherence inhibition (LAI), CA 19-9, and the tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer. Cancer 1989; 64:1103–1106.

    Article  PubMed  CAS  Google Scholar 

  86. Andriulli A, Gindro T, Piantino P, et al. Efficacy of CA 19-9, TPA and CEA assays in pancreatic cancer. Digestion 1983; 28:9–10.

    Article  Google Scholar 

  87. Panucci A, Fabris C, Del Favero G, et al. Tissue polypeptide antigen (TPA) in pancreatic cancer diagnosis. Br J Cancer 1985; 52:801–803.

    Article  PubMed  CAS  Google Scholar 

  88. Pasanen P, Eskelinen M, Partanen K, et al. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Anticancer Res 1993; 13:1883–1888.

    PubMed  CAS  Google Scholar 

  89. Plebani M, Basso D, Del Favero G, et al. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer. Oncology 1993; 50:436–440.

    Article  PubMed  CAS  Google Scholar 

  90. Kornek G, Schenk T, Djavarnmad M, and Scheithauer W. Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumors. Br J Cancer 1995; 71:182–185.

    Article  PubMed  CAS  Google Scholar 

  91. Basso D, Fabris C, Piccoli A, et al. Serum tissue polypeptide antigen in pancreatic cancer and other gastrointestinal diseases. J Clin Pathol 1989; 42:555–557.

    Article  PubMed  CAS  Google Scholar 

  92. Greenway B, Iqbal MJ, Johnson PJ, and Williams R. Oestrogen receptor protein in malignant and foetal pancreas. Brit Med J 1981; 283:751–753.

    Article  CAS  Google Scholar 

  93. Greenway B, Iqbal MJ, Johnson PJ, and Williams R. Low serum testosterone levels in patients with carcinoma of the pancreas. Br Med J 1983; 286:93–95.

    Article  CAS  Google Scholar 

  94. Iqbal MJ, Greenway B, Wilkinson ML, et al. Sex steroid enzymes aromatase and reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin Sci 1983; 65:71–75.

    PubMed  CAS  Google Scholar 

  95. Fernandez del Castillo C, Díaz-Sanchez V, and Robles-Díaz G. Pancreatic cancer and androgen metabolism: high androstenedione and low testosterone serum levels. Pancreas 1990; 5:515–518.

    Article  PubMed  CAS  Google Scholar 

  96. Shearer NG, Taggart D, and Gray C. Useful differentiation between pancreatic carcinoma and chronic pancreatitis by testosterone assay. Digestion 1984; 30:106–107.

    Google Scholar 

  97. Todd BD. Pancreatic carcinoma and low serum testosterone: a correlation secondary to cancer cachexia? Eur J Surg Oncol 1988; 14:199–202.

    PubMed  CAS  Google Scholar 

  98. Sperti C, Bonadimani B, Militello C, et al. Testosterone and androgen metabolism in pancreatic cancer. J Clin Gastroenterol 1992; 15:161–162.

    PubMed  CAS  Google Scholar 

  99. Fernandez del Castillo C, Diaz-Sanchez V, Varela-Fascinetto V, et al. Testosterone bio-transformation by the isolated perfused canine pancreas. Pancreas 1991; 6:104–111.

    Article  PubMed  CAS  Google Scholar 

  100. Robles-Díaz G, Díaz-Sanchez V, Mendez JP, et al. Low serum testosterone/dihydrotestosterone ratio in pancreatic carcinoma. Pancreas 1987; 2:684–687.

    Article  PubMed  Google Scholar 

  101. Robles-Díaz G, Díaz-Sanchez V, Fernandez-del Castillo C, et al. Serum testosterone/dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer. Am J Gastroenterol 1991; 86:591–594.

    PubMed  Google Scholar 

  102. Clark A, de Koning EJ, Hattersley AT, et al. Pancreatic pathology in non-insulin dependent diabetes. Diabetes Res Clin Pract 1995; 28(Suppl):S39–47.

    Article  Google Scholar 

  103. Oosterwijk C, Hoppener JW, van Hulst KL, and Lips CJ. Pancreatic islet amyloid formation in patients with noninsulin-dependent diabetes mellitus. Implication for a therapeutic strategy. Int J Pancreatol 1995; 18:7–14.

    CAS  Google Scholar 

  104. Arnelo U, Larsson J, Permert J, et al. Could islet amyloid polypeptide contribute to the cachexia of pancreatic cancer? Gastroenterology 1993; 104(Suppl):A294.

    Google Scholar 

  105. Stridsberg M, Eriksson B, Skogseid B, et al. Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumors. Regul Peptides 1995; 55:119–131.

    Article  CAS  Google Scholar 

  106. Permert J, Larsson J, Westermark G, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994; 330:313–318.

    Article  PubMed  CAS  Google Scholar 

  107. Satake K, Kanazawa G, Kho I, et al. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9 and carcinoembryonic antigen in various pancreatic diseases. Am J Gastroenterol 1985; 80:630–636.

    PubMed  CAS  Google Scholar 

  108. Sakahara H, Endo K, Nakajima K, et al. Serum CA 19-9 Concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57:1324–1326.

    Article  PubMed  CAS  Google Scholar 

  109. Iishi H, Yamamura H, and Tatsuta M. Value of ultrasonic examination combined with measurement of serum tumor marker in the diagnosis of pancreatic cancer of less than 3 cm in diameter. Cancer 1986; 57:1947–1951.

    Article  PubMed  CAS  Google Scholar 

  110. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90:343–349.

    PubMed  CAS  Google Scholar 

  111. Safi F, Beger H, Bittner R, et al. CA 19-9 and pancreatic adenocarcinoma. Cancer 1986; 57:779–783.

    Article  PubMed  CAS  Google Scholar 

  112. Del Favero G, Fabris C, Plebani M, et al. CA 19-9 and carcinoembryonic antigen in pancreatic cancer. Cancer 1986; 57:1576–1579.

    Article  PubMed  Google Scholar 

  113. Wang TH, Lin JW, Chen DS, et al. Noninvasive diagnosis of advanced pancreatic cancer by real-time ultrasonography, carcinoembryonic antigen and carbohydrate antigen 19-9. Pancreas 1986; 1:219–223.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Carlos Rollhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Steinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. UCLA School of Medicine, Los Angeles, CA, USA

    Howard A. Reber MD

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rollhauser, C., Steinberg, W. (1998). Tumor Antigens in Pancreatic Cancer. In: Reber, H.A. (eds) Pancreatic Cancer. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-1810-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1810-4_7

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4612-7294-6

  • Online ISBN: 978-1-4612-1810-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation